The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

The LEGEND trial showed a 62% complete response (CR) rate with the non-viral gene therapy at six months in NMIBC patients who ...

ADVANCED-2 (NCT05951179) is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive ...

This year's Genitourinary Cancers Symposium featured multiple studies on therapies in development for non-muscle-invasive bladder cancer. In this exclusive video, Gary Steinberg, MD, from the ...

Gene's Phase 2 LEGEND trial shows 63% response in BCG-unresponsive bladder cancer, supporting plans for a 2026 FDA filing.

Patients with initially low- or intermediate-risk primary tumors will often have a high-risk recurrence before progressing to more advanced disease, whereas primary high-risk tumors typically show ...

Engene Holdings Inc.’s protocol amendment to its phase II trial with detalimogene voraplasmid in bladder cancer worked out in ...

TAR-200, a gemcitabine-releasing system, received FDA priority review for high-risk non-muscle invasive bladder cancer unresponsive to BCG. Phase 2b SunRISe-1 trial data showed an 82.4% complete ...

The MarketWatch News Department was not involved in the creation of this content. -- ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate ...

The company announced that detalimogene demonstrated a 62% complete response rate at 6 months in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

Many other health problems can also cause these signs. If you have any of these signs, see your doctor as soon as possible. Learn more about bladder cancer from the National Cancer Institute. Image of ...

Urothelial cancers that are either non-invasive papillary (Ta), carcinoma in situ (CIS) flat tumors, or invade the subepithelial connective tissue (T1) are collectively termed non-muscle-invasive ...